Announced Mon, 13 Jul · 16:22 IST
Emcure buys remaining 12.05% in Gennova for Rs 231.87 crore
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹1791.00
prior close
₹1789.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.6+2.0+2.6+2.4+0.1+0.5-0.4+4.0+7.8+4.6————
Up moveDown movePending
AI summary
Emcure Pharmaceuticals is buying the remaining 12.05% stake (6,63,865 shares) in subsidiary Gennova Biopharmaceuticals for Rs 2,318.7 million in cash, making it a wholly-owned subsidiary. Gennova posted FY26 revenue of Rs 4,917.42 million and profit of Rs 54.25 million. Deal with related parties, done at arm's length. Completion expected by July 31, 2026.
Likely market impact
Consolidation move giving full control of biotech arm and simpler structure. Cash outflow of about Rs 232 crore, modest relative to Emcure's overall size.